Clinical Trials Logo
  1. Home
  2. CLL
  3. NCT05517265

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) — CICERO  

CLL Clinical Trial

Official title:
A Non-interventional, Prospective, Open-label, Observational Study Evaluating the Effectiveness and Safety of Acalabrutinib (Calquence®) in Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Direct Oral Anticoagulation (DOAC).

Clinical Trial Summary

The goal of CICERO is to investigate the clinical outcome with a particular focus on prospective data on safety using acalabrutinib (+/- obinutuzumab) in CLL patients receiving co-medication with DOACs (edoxaban, rivaroxaban, dabigatran, apixaban) irrespective of treatment line.

Clinical Trial Description

The non-interventional study (NIS) CICERO will collect real-world data to explore acalabrutinib (+/- obinutuzumab) in adult CLL patients (irrespective of treatment line) who receive co-medication with DOACs. The primary focus of the study is to investigate the incidence proportion of bleeding events. Due to the mostly elderly CLL patient population, CLL patients often suffer from multiple cardiovascular comorbidities including atrial fibrillation (AF), deep vein thrombosis (DVT) or pulmonary embolism (PE) which make anticoagulation mandatory. Up to now, no systematic and prospective evaluation on interactions of BTKis and DOACs has been conducted. In Order to assess bleeding events, a questionnaire will be used to document if bleeding events occurred in-between visits in routine care. Patients will be asked at each visit if distinct events occurred in the time between the last visit until the current visit and discuss the questionnaire with the physician to determine of any (S)AE occurred until end of acalabrutinib treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05517265
Study type Observational
Source iOMEDICO AG
Contact Daniel Kummer, Dr.
Phone +49761152420
Email Cicero@iomedico.com
Status Recruiting
Phase
Start date October 12, 2022
Completion date October 12, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02229422 - A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) Phase 1/Phase 2
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01862445 - Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Completed NCT00535873 - Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older Phase 2
Withdrawn NCT03639324 - Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Phase 1
Recruiting NCT03868722 - Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment Phase 2/Phase 3
Recruiting NCT04640909 - Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients N/A
Recruiting NCT05610228 - Study of the Metabolism in the Lymphatic Niche of CLL
Completed NCT01168921 - Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Phase 2
Withdrawn NCT05209308 - Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Phase 2
Completed NCT00792077 - A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue Phase 2
Recruiting NCT06073821 - Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Phase 3
Recruiting NCT05246345 - Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01703364 - Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Phase 1/Phase 2
Terminated NCT03572634 - Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Phase 1/Phase 2
Completed NCT03231579 - Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
Completed NCT00636909 - Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Phase 2
Active, not recruiting NCT03524235 - Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Phase 1
Active, not recruiting NCT04746092 - The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19